title: [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication.
abstract: The recently developed radioligand [123I]FP-CIT is suitable for clinical single-photon emission tomography (SPET) imaging of the dopamine (DA) transporter in vivo. To date it has remained unclear whether dopaminergic medication influences the striatal [123I]FP-CIT binding. The purpose of this study was to investigate the influence of this medication on [123I]FP-CIT binding in the brain. We used an animal model in which we administered dopaminomimetics, antipsychotics and an antidepressant. In vivo [123I]FP-CIT binding to the DA and serotonin transporters was evaluated after subchronic and acute administration of the drugs. The administered medication induced small changes in striatal [123I]FP-CIT binding which were not statistically significant. As expected, the DA reuptake blocker GBR 12,909 induced a significant decrease in [123I]FP-CIT binding. [123I]FP-CIT binding in the serotonin-rich hypothalamus was decreased only after acute administration of fluvoxamine. The results of this study suggest that dopaminergic medication will not affect the results of DA transporter SPET imaging with [123I]FP-CIT.
authors.affiliation: Graduate School of Neurosciences Amsterdam, Department of Nuclear Medicine, Academic Medical Center, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Lavalaye
authors.forename: R J
authors.initials: RJ
authors.lastname: Knol
authors.forename: K
authors.initials: K
authors.lastname: de Bruin
authors.forename: L
authors.initials: L
authors.lastname: Reneman
authors.forename: A G
authors.initials: AG
authors.lastname: Janssen
authors.forename: J
authors.initials: J
authors.lastname: Booij
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism*; D002531:Cerebellum / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D007031:Hypothalamus / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014326:Tropanes / Q000493:pharmacokinetics*
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018765:Dopamine Uptake Inhibitors; D007457:Iodine Radioisotopes; D010879:Piperazines; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane; C043425:vanoxerine